Anti-human TIGIT monoclonal antibody TIGIT-M006 or functional fragment thereof and application thereof

Through screening of the phage antibody library of immune mice, high affinity and high specificity TIGIT monoclonal antibodies were obtained, which solved the problem of limited effect of existing TIGIT monoclonal antibodies, achieved efficient recognition and binding of TIGIT proteins, and provided a new tumor treatment strategy.

CN119751676AActive Publication Date: 2025-04-04BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
3 Cites 0 Cited by

Patent Information

Application Number
CN202411470575.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-10-11
Publication Date
2025-04-04
Estimated Expiration
2043-10-11

AI Technical Summary

Technical Problem

The existing TIGIT monoclonal antibody has limited effect in tumor treatment, and there are insufficient preparation technology, making it difficult to obtain high affinity and high specificity antibodies.

Method used

Through the screening of the immunized mouse phage antibody library, high-performance monoclonal antibodies TIGIT-M001, TIGIT-M003, TIGIT-M006, TIGIT-M007, TIGIT-M011 and TIGIT-M013 were obtained. These antibodies have high sensitivity, high specificity and high affinity, and can specifically recognize and bind human TIGIT proteins.

Benefits of technology

These antibodies significantly improve binding affinity with TIGIT proteins, can effectively regulate immune cell activity, and provide potential new ways to treat tumors.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedicine and antibody engineering. The invention relates to the field of immunoconjugates, in particular to an anti-human TIGIT monoclonal antibody TIGIT-M006 or a functional fragment thereof and application of the anti-human TIGIT monoclonal antibody TIGIT-M006 or the functional fragment thereof as an immunoconjugate, a chimeric antigen receptor and / or a composition, and particularly discloses a monoclonal antibody capable of binding to human TIGIT protein or an antigen binding fragment thereof. The TIGIT specific monoclonal antibody obtained by screening has high sensitivity, high specificity and high affinity.
Need to check novelty before this filing date? Find Prior Art